Press Releases
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Positive trend was observed in seven of eight IPF biomarkers evaluated Low-dose LTI-03 was well-tolerated, with no safety…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Aubex Therapeutics Inc., a pioneering biotechnology firm, announced its official launch, heralding a new era in the battle against cancer. Under the guidance of Board Member and Interim CEO, Jeffrey Glazer, Aubex’s initial program is focused on novel compounds aimed at transforming the treatment of solid tumor malignancies…
Read More
Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa. Aldeyra will present new preclinical…
Read More
Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Excerpt from the Press Release: SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the…
Read More
Excerpt from the Press Release: BOSTON, April 25, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in…
Read More
Excerpt from the Press Release: SAN FRANCISCO, April 25, 2024 /PRNewswire/ — Freedom Biosciences, Inc. (“Freedom Bio” or the “Company”), a clinical-stage biotechnology platform focused on developing next-generation neuropsychiatric therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its FREE001-TRD-201 study for its lead program, FREE001,…
Read More
Excerpt from the Press Release: First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy SAN DIEGO, April 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron…
Read More
-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- – BB-301 facilitated improvements across multiple measures of swallowing function in the first Phase 1b/2a clinical study subject as compared to pretreatment assessments conducted during the observational natural history portion of the study- Excerpt from…
Read More
Excerpt from the Press Release: In the news release, D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study … issued 18-Apr-2024 by D2M Biotherapeutics, Inc. over PR Newswire, the headline was incorrectly separated by PR Newswire into two parts. The corrected release (with headline intact) follows: D2M Biotherapeutics Announces First Patient Dosed in…
Read More Excerpt from the Press Release: SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients…
Read More